### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

Sunda	nce Resources Limited	
ABN		
19 055	5 719 394	
We (tl	he entity) give ASX the following	information.
	1 - All issues ast complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully Paid Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	55,000,000 fully paid ordinary shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares
4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	The shares will rank equally in all respects with existing fully paid ordinary shares.
5	Issue price or consideration	Nil

Name of entity

Appendix 3B Page 1 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of Shares to Senior Staff
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> * <i>securities the subject of this Appendix</i> 3 <i>B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29/11/17
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	55,000,000
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market	7.1 capacity - <b>1,218,877,043</b> 7.1A capacity - <b>812,584,695</b>

<sup>+</sup> See chapter 19 for defined terms.

Announcements

Appendix 3B Page 2 04/03/2013

_	+1	1
7	<sup>+</sup> Issue	uates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

26 June 2018			

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
8,125,846,952	Fully paid ordinary shares

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

	Г
Number	<sup>+</sup> Class
	UNLISTED OPTIONS
260,000,000	Investor Consortium Options
	exercisable at \$0.0695 per
	option
200,000,000	Noble Options exercisable at
	\$0.0695 per option
252 222 222	
260,000,000	Wafin Options exercisable at
	\$0.0695 per option
100,000,000	2017 Options exercisable at \$0.003
100,000,000	per option vesting 1/12/2017
	expiring 7/4/2022
	CXPIIIIG 77-72022
100,000,000	2017 Options exercisable at \$0.006
, ,	per option vesting 1/12/2018
<u></u>	expiring 7/4/2023
920,000,000	
	CONVERTIBLE NOTES
200,000	Noble
240,000	Investor Consortium
400,000	Wafin
70,000	2015 Investor Group
2,600	2016 Investor Group
912,600	·

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

### Part 2 - Pro rata issue

Is security holder approval required?

N/A			

Appendix 3B Page 3 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	N/A
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
19	-	N/A
	acceptances or renunciations	
20	acceptances or renunciations  Names of any underwriters  Amount of any underwriting fee	N/A
20	acceptances or renunciations  Names of any underwriters  Amount of any underwriting fee or commission	N/A N/A
20 21 22	acceptances or renunciations  Names of any underwriters  Amount of any underwriting fee or commission  Names of any brokers to the issue  Fee or commission payable to the	N/A  N/A
20 21 22 23	acceptances or renunciations  Names of any underwriters  Amount of any underwriting fee or commission  Names of any brokers to the issue  Fee or commission payable to the broker to the issue  Amount of any handling fee payable to brokers who lodge acceptances or renunciations on	N/A  N/A  N/A
20 21 22 23 24	Amount of any underwriting fee or commission  Names of any brokers to the issue  Fee or commission payable to the broker to the issue  Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders  If the issue is contingent on security holders' approval, the	N/A  N/A  N/A  N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
	B - Quotation of securities I only complete this section if you are app	
34	Type of <sup>+</sup> securities ( <i>tick one</i> )	
(a)	*Securities described in Part	1
(b)	All other *securities	
		nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitie	s that have ticked box 34(a)	
Additi	onal securities forming a new	class of securities
Tick to 35		on or documents securities, the names of the 20 largest holders of the the number and percentage of additional <sup>+</sup> securities

+ See chapter 19 for defined terms.

1 - 1,000

36

Appendix 3B Page 5 04/03/2013

\*securities setting out the number of holders in the categories

If the  ${}^{\scriptscriptstyle +}\!\!$ securities are  ${}^{\scriptscriptstyle +}\!\!$ equity securities, a distribution schedule of the additional

1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

A copy of any trust deed for the additional \*securities

### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not		
	<ul> <li>rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now Example: In the case of restricted securities, end		
	of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		Ciuss

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company Secretary)

Print name: CAROL MARINKOVICH

== == == ==

Appendix 3B Page 7 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	7,102,023,617	
<ul> <li>Add the following:</li> <li>Number of fully paid +ordinary</li> </ul>	384,133 (options exercised under the	
securities issued in that 12 month period under an exception in rule 7.2	Entitlement Offer dated 3 February 2016) 11 August 2017	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary</li> </ul>	3,174,715 (options exercised under the Entitlement Offer dated 3 February 2016) 25 August 2017	
securities that became fully paid in that 12 month period  Note: Include only ordinary securities here –	42,610,469 (options exercised under the Entitlement Offer dated 3 February 2016) 7 September 2017	
<ul> <li>other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>	5,400 (options exercised under the Entitlement Offer dated 3 February 2016) 7 September 2017	
It may be useful to set out issues of securities on different dates as separate line items	386,044,838 (Issued under Share Purchase Plan announced 25 August 2017) 25 September 2017	
	92,115,144 (Top-up Placement to sophisticated investors announced 25 August 2017) 25 September 2017	
	Approved by Shareholders 29 November 2017	
	147,345,679 (issue to Hanlong) 4 December 2017	
	185,714,286 (issue to Noble) 13 February 2018	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

"A"	8,125,846,952
Subtract the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil
	55,000,000 (issued to staff) 26 June 2017
	100 shares issued under Cleansing Prospectus 10 April 2018
	111,428,571 (issue to Senrigan) 26 February 2018

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	1,218,877,043
Step 3: Calculate "C", the amount of placement capacity under rule	

### 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on

"C" Nil

#### Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15 Note: number must be same as shown in Step 2	1,218,877,043
Subtract "C"  Note: number must be same as shown in Step 3	Nil
<b>Total</b> ["A" x 0.15] – "C"	1,218,877,043

<sup>+</sup> See chapter 19 for defined terms.

different dates as separate line items

04/03/2013 Appendix 3B Page 9

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	8,125,846,952	
Step 2: Calculate 10% of "A"		
"D"	0.10  Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	812,584,695	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	Nil	
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	812,584,685
Subtract "E" Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" x 0.10] – "E"	812,584,695

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.